



# RADIOTERAPIJSKE TEHNIKE



doc dr Neda Milosavljević

# PODELA RADIOTERAPIJE PREMA UDALJENOSTI IZVORA ZRAČENJA

- Iz neposredne blizine (brahiterapija)
- Sa određene distance od površine tela i/ili tumora (teleradioterapija, transkutana radioterapija).


# Radioterapijski aparati – linearni akceleratori

- Kilovoltažne mašine – produkuju X-zrake energija  $< 500 \text{ kV}$ .
- Koriste se za tretman površnih lezija
- Megavoltažne mašine – produkuju zračenje energija  $> 1\text{MV}$
- Linearni akceleratori (savremene teleterapijske mašine)

# Ro simulator





# CT/MR simulator



- Andres A. E. Int J of Radiation Oncology, Biology, Physics. , 2020.



# PRECIZNA ISPORUKA MAKSIMALNE RADIOTERAPIJSKE DOZE U TUMORSKOM TKIVU UZ MINIMALNO OŠTEĆENJE OKOLNOG, ZDRAVOG TKIVA






2007 VARIAN courtesy

(b)



Lee S. 2014.  
Evolution of Ionizing Radiation Research




- Konformalna radioterapija (CRT) – počeci 1960.
- Razvoj imaging metoda (CT, MRI, PET), informacione tehnologije, savremeni radioterapijski uređaju - omogućen razvoj CRT
- Lokalna kontrola bolesti u funkciji isporučene doze
- Pošteda okolnih, zdravih tkiva
- Eskalacija doze

# Target volumeni


- Gross Tumor Volume (GTV): vidljivi deo tumora (ili limfnog čvora), na osnovu urađenih kliničko-dijagnostičkih procedura. Nakon radikalno operisanog tumora (R0 resekcija) GTV nije vidljiv.
- Clinical Target Volume (CTV): obuhvata zonu mikroskopskog širenja malignih ćelija oko vidljivog dela tumora. Takođe, oko uvećanih regionalnih limfnih čvorova (GTVn) se definiše CTVn, a on po pravilu obuhvata najmanje cijelu anatomsку grupu limfnih čvorova kojoj pripada involvirani čvor.
- Planning Target Volume (PTV): margina koja pokriva interfrakcijske/ intrafrakcijske varijacije položaja CTV-a u odnosu na geometriju snopa/polja zračenja, a nastaje zbog: varijacija u preciznosti, fizioloških pokreta.


# Organs at Risk (OAR - organi pod rizikom)


- Zdrava, okolna tkiva, o čijoj poštedi/radiosenzitivnosti se vodi računa pri izradi plana zračenja i sprovođenju lečenja radioterapijom
- Dodatni volumen oko OAR (PRV - Planning Risk Volume)
- 3D model „virtuelnog pacijenta”, s volumnim prikazom geometrije ciljnog volumena i prostornih odnosa ciljnog volumena i OAR



Icru 52.








# POZICIONIRANJE I IMOBILIZACIJA PACIJENTA

- Prva odluka u procesu planiranja radioterapije je pozicioniranje
- Zavisi od lokalizacije tumora i imobilizacionih uređaja koji su na raspolaganju
- I više od 30 radioterapijskih frakcija tokom jednog tretmana - bitno adekvatno pozicioniranje i imobilizacija koji treba da omoguće visoku preciznost u sprovođenju planirane RT




**QUANTEC Summary:**  
**Approximate Dose/Volume/Outcome Data for Several Organs Following Conventional Fractionation 3D-CRT**

Organ	Endpoint	Dose (Gy), or dose/volume parameters	Rate (%)	Volume segmented	Irradiation type (partial organ unless otherwise stated)
<b>Brain</b>	Symptomatic necrosis	Dmax <60	<3	Whole organ	3D-CRT
		Dmax = 72	5		
		Dmax = 90	10		
<b>Brain stem</b>	Permanent cranial neuropathy or necrosis	Dmax <54	<5	Whole organ	Whole organ
		D1–10 cc * ≤59	<5		3D-CRT
		Dmax <64 <<1 cc (Point dose)	<5		3D-CRT
<b>Optic nerve/chiasm</b>	Optic neuropathy	Dmax <55	<3	Whole organ	Given the small size, 3D-CRT is often whole organ
		Dmax 55–60	3–7		
		Dmax >60	>7–20		
<b>Spinal cord</b>	Myelopathy	Dmax = 50	0.2	Partial organ	3D-CRT
		Dmax = 60	6		
		Dmax = 69	50		
<b>Cochlea</b>	Sensory neural hearing loss (hearing at 4 kHz)	Mean dose ≤45	<30	Whole organ	Given the small size, 3D-CRT is often whole organ
<b>Parotid</b>	Long term parotid salivary function reduced to <25% of pre-RT level	Mean dose <25 (for combined parotid glands)**	<20	Bilateral whole parotid glands	3D-CRT
		Mean dose <20 (for single parotid gland)**	<20	Unilateral whole parotid gland	
		Mean dose <39 (for combined parotid glands)**	<50	Bilateral whole parotid glands	
<b>Pharynx constrictors</b>	Symptomatic dysphagia and aspiration	Mean dose <50	<20	Pharyngeal constrictors	Whole organ
<b>Larynx</b>	Vocal dysfunction (with chemo, based on single study)	Dmax <66	<20	Whole organ	3D-CRT
	Aspiration (with chemo, based on single study)	Mean dose <50	<30		
	Edema (without chemo, based on single study in patients without larynx cancer)	Mean dose <44 V50 <27%	<20 <20		
<b>Lung</b>	Symptomatic pneumonitis	V20 ≤ 30% (for combined lung)	<20	Whole organ	3D-CRT
		Mean dose = 7	5		3D-CRT (excludes purposeful whole lung irradiation)
		Mean dose = 13	10		
		Mean dose = 20	20		
		Mean dose = 24	30		

# 3D CRT


- Trodimenzionalna (3D) konformalna radioterapija je precizna tehnika, koja se bazira na trodimenzionalnom volumetrijskom definisanju tumora i okolnih zdravih organa.
- Predstavlja minimum standarda danas
- Koristi se prethodnih 20 godina




File Edit View Measure Structure 4D Tools

Selection Contouring Image Registration External Beam Planning Brachytherapy Planning Brachytherapy 2D Entry Plan Evaluation


Transversal - CT\_1 - 12/3/2021 9:17 AM



Sagittal - CT\_1 - 12/3/2021 9:17 AM





Frontal - CT\_1 - 12/3/2021 9:17 AM





Standard, MFS  
E: 2.25 cm


(oncology)aca 1/20/2022 3:45 PM ✓













Fields	Dose	Reference Points	Dose Statistics	Group	Field ID	Technique	Machine/Energy	MLC	Field Weight	Scale	Gantry Angle [deg]	Coll Rtn [deg]	Iso Rtn [deg]	Wedge	Field X [cm]	X1 [cm]	X2 [cm]	Field Y [cm]	Y1 [cm]	Y2 [cm]	X [cm]	Y [cm]	Z [cm]	Calculated SSD [cm]	MU	Ref. D [cGy]
				I	pi0	STATIC-I	Elekta3 - 6X		0.000	IEC61217	0.0	0.0	0.0	None	22.0	-11.0	+11.0	18.1	-7.1	+11.0	-0.85	4.05	4.09	85.8		
				I	pi90	STATIC-I	Elekta3 - 6X		0.000	IEC61217	90.0	0.0	0.0	None	18.5	-11.0	+7.5	17.5	-6.5	+11.0	-0.85	4.05	4.09	80.8		
				I	foto	STATIC-I	Elekta3 - 6X		0.000	IEC61217	0.0	0.0	0.0	None	10.4	-5.4	+5.0	12.6	-9.6	+3.0	-0.85	4.05	4.09	85.8		
				I	48	STATIC-I	Elekta3 - 6X	Static	0.419	IEC61217	48.7	0.0	0.0	None	18.3	-7.8	+10.5	11.2	-5.5	+5.7	-0.85	4.05	4.09	81.3	38	56.8
				I	48.0	STATIC-I	Elekta3 - 6X	Static	0.081	IEC61217	48.7	0.0	0.0	None	18.2	-7.3	+10.9	12.0	-6.0	+6.0	-0.85	4.05	4.09	81.3	7	11.1
				I	79	STATIC-I	Elekta3 - 6X	Static	0.329	IEC61217	79.2	0.0	0.0	None	15.0	-8.8	+6.2	10.5	-5.0	+5.5	-0.85	4.05	4.09	80.1	37	56.4
				I	79.0	STATIC-I	Elekta3 - 6X	Static	0.071	IEC61217	79.2	0.0	0.0	None	13.3	-8.1	+5.2	12.0	-6.0	+6.0	-0.85	4.05	4.09	80.1	8	12.6

Ready

User: dr Nedra Milosavljevic Group: Oncologist Site: Main CAP\_NUM SCR






JOVVER211203

 R1 : R0  
 Plan\_1

## Dose Volume Histogram




**Plan\_1**


- Registered Images
  - CT\_1
    - BODY
    - CouchInterior
    - CouchSurface
    - CTV\_High
    - Esophagus
    - gtvN
    - gTVp
    - Heart
    - Lung\_L
    - Lung\_R
    - PTV\_High
    - SpinalCord
- User Origin
- Reference Points
  - PTV\_High
- Dose
- Fields
  - Isocenter Group I
    - p0
    - p10-DRR (Live)
    - p100
    - p120-DRR (Live)
    - foto
    - foto-DRR (Live)
    - 48
    - Field 3-DRR (Live)
    - MLC
  - 48.0
    - Field3-DRR (Live)
    - MLC
  - 79
    - Field 5-DRR (Live)

Structure	Approval Status	Plan	Course	Volume [cm³]	Dose Cover[%]	Sampling Cover[%]	Min Dose [cGy]	Max Dose [cGy]	Mean Dose [cGy]	D50% [ % ]	V95.0% [ % ]	V107.0% [ % ]	V107.0% [cm³]	V5320.0cGy [%]	V5985.0cGy [%]	V5992.0cGy [%]	V6650.0cGy [%]
Lung_L	Approved	Plan_1	1	1720.1	100.0	100.0	35.3	6944.9	2876.0	0.0	18.6	0.1	1.3180	29.5	20.1	20.0	4.8
Lung_R	Approved	Plan_1	1	2523.3	100.0	100.0	43.2	6773.6	1331.9	0.0	1.9	0.0	0.0000	3.8	2.2	0.0	0.0
BODY	Approved	Plan_1	1	21699.8	100.0	100.2	1.0	6984.6	1137.3	0.0	4.1	0.0	6.6403	6.1	4.4	0.9	0.1
Esophagus	Approved	Plan_1	1	29.0	100.0	100.2	100.1	6723.9	3170.9	0.0	38.3	0.0	0.0000	41.8	39.3	39.3	0.1
SpinalCord	Approved	Plan_1	1	37.9	100.0	99.4	6.3	4685.6	1195.3	0.0	0.0	0.0	0.0000	0.0	0.0	0.0	0.0
Heart	Approved	Plan_1	1	363.5	100.0	100.0	101.0	535.7	232.4	0.0	0.0	0.0	0.0000	0.0	0.0	0.0	0.0
gTVp	Approved	Plan_1	1	83.5	100.0	100.0	6054.7	6944.7	6621.3	0.0	100.0	0.7	0.5707	100.0	100.0	100.0	44.8
gtvN	Approved	Plan_1	1	27.3	100.0	100.0	5954.0	6984.6	6366.0	0.0	96.5	0.6	0.1578	100.0	100.0	100.0	12.1
CTV_High	Approved	Plan_1	1	277.0	100.0	100.0	5604.9	6984.6	6523.2	0.0	99.0	0.6	1.7779	100.0	99.9	99.9	34.2
PTV_High	Approved	Plan_1	1	710.4	100.0	100.0	4273.5	6984.6	6453.5	0.0	95.0	0.6	4.2090	99.9	97.0	96.9	24.3
= (Lung_L OR Lung_R) S...	Approved	Plan_1	1	3946.6	100.0	100.0	35.3	6857.6	1619.8	1.5	1.5	1.5	1.#QNB	1.5	1.5	1.5	1.5

# INTENSITY MODULATED RADIATION THERAPY - IMRT

- Konformalna radioterapijska tehnika – eskalacija doze na jasno definisani ciljni volumen i strm gradijent doze prema kritičnim strukturama
- Moguće je da u okviru volumena (tumora) doza varira (nije homogena), što se postiže modulacijom svakog snopa – npr simultani integrисани boost.
- Zasniva se na primeni više zračnih polja, podeljenih u segmentna polja
- Tokom svake frakcije kompjuterski kontrolisanim pomeranjem lamela MLC oblik zračnog polja se više puta sukcesivno ili kontinuirano dinamički menja






Some structures are unapproved or reject

# Volumetric Modulated Arc Therapy, VMAT


- Omogućava isporuku visoke doze na metu, odnosno tumor, u jednom ili pola luka.
- Obezbeđuje najveću homogenost distribucije doze.
- Doza se isporučuje na čitav ciljni volumen, a ne „slajs po slajs” kao što je to slučaj kod primene drugih tehnika.
- U poređenju sa IMRT, ima bolju pokrivenost mete i kvalitetniju zaštitu organa od rizika.
- Kraće trajanje tretmana, što direktno smanjuje mogućnost za interfrakcijsko pomeranje organa.
- Mana VMAT tehnike je ta što veći deo zdravog tkiva koji se nalazi u zračnoj regiji prima manju dozu.




File Edit View Measure Structure 4D Tools

Selection Contouring Image Registration External Beam Planning Brachytherapy Planning Brachytherapy 2D Entry Plan Evaluation

Transversal - CT\_1 - 4/6/2021 8:55 AM



3D - CT\_1 - 4/6/2021 8:55 AM




Drawing Tools


Select Structures



- Draw Planar Contour
- Brush
- Eraser
- Draw Geometrical Shape
- Create or Edit Annotation
- Draw Volumetric Contour
- Transform Structure
- Deform Structure
- PET Subvolume Thresholding
- Image Thresholding
- Search Body
- Segmentation Wizard
- Flood Fill
- Margin for Structure
- Post Processing
- Extract Wall
- Crop Structure
- Boolean Operators
- Extend Segmentation
- Interpolate Structure
- Segment High Density Artifacts
- Clear Structure
- Move Marker or Isocenter Marker
- Edit Reference Points
- Draw Reference Line
- Calypso Beacon Detection


Frontal - CT\_1 - 4/6/2021 8:55 AM




Sagittal - CT\_1 - 4/6/2021 8:55 AM











# *OAR constrains*

Mokraćna bešika	V65 < 50% V70 < 35% V75 < 25% V80 < 15%
Sigmoidni kolon	V50 < 50% V60 < 35% V65 < 25% V70 < 20% V75 < 15%
Rektum	V50 < 50% V60 < 35% V65 < 25% V70 < 20% V75 < 15%
Creva	V45 < 195 cm <sup>3</sup> V15 < 120 cm <sup>3</sup>
Femur	V40 < 40% V45 < 25% V50 < 10%


- Kang SW, Chung JB, Kim JS, Kim IA, Eom KY, Song C, Lee JW, Kim JY, Suh TS. Optimal planning strategy among various arc arrangements for prostate stereotactic body radiotherapy with volumetric modulated arc therapy technique. Radiol Oncol. 2017 Jan 15;51(1):112-120.





KaraVido010421

- 1
  - PD\_66Gy
  - PD\_66Gy
  - 72Gy
- PTV66 : R0
- 66Gy
- PTV72 : R0
- 6Gy



- 72Gy
- CT\_1
  - Registered Images
  - CT\_1
    - Bladder
    - BODY
    - Bowel
    - CTV
    - CTV\_p+sv
    - FemHeadNeck\_L
    - FemHeadNeck\_R
    - NS\_Ring
    - NS\_Ring1
    - PTV\_6600
    - PTV\_7200
    - Rectum
    - SeminalVesicle
    - Sigma
  - User Origin
- Reference Points
  - PTV\_6600
  - PTV\_7200
  - Verification
  - Verification1
- Dose
- 66Gy
- Fields
  - Isocenter Group 1
    - PO
    - P20
    - CBCT
    - G181-179
    - G179-181
- 6Gy
- Fields

Reference Points Dose Statistics

Show DVH	Structure	Approval Status	Plan	Course	Volume [cm³]	Dose Cover.[%]	Sampling Cover.[%]	Min Dose [cGy]	Max Dose [cGy]	Mean Dose [cGy]
<input checked="" type="checkbox"/>	BODY	Approved	72Gy	1	28289.4	100.0	100.1	0.0	7455.3	641.7
<input checked="" type="checkbox"/>	Bladder	Approved	72Gy	1	709.0	100.0	100.0	91.5	7365.6	2229.9
<input checked="" type="checkbox"/>	Bowel	Approved	72Gy	1	202.4	100.0	100.0	11.0	198.3	48.2
<input checked="" type="checkbox"/>	CTV	Approved	72Gy	1	62.0	100.0	100.0	6992.7	7351.4	7149.1
<input checked="" type="checkbox"/>	CTV_p+sv	Approved	72Gy	1	77.4	100.0	100.0	6534.5	7351.4	7110.4
<input checked="" type="checkbox"/>	FemHeadNeck_L	Approved	72Gy	1	292.8	100.0	100.0	36.1	3381.7	1311.8
<input checked="" type="checkbox"/>	FemHeadNeck_R	Approved	72Gy	1	289.6	100.0	100.0	38.2	3156.0	1155.8
<input checked="" type="checkbox"/>	NS_Ring	Approved	72Gy	1	2500.9	100.0	100.0	128.5	7271.6	2781.2
<input checked="" type="checkbox"/>	NS_Ring1	Approved	72Gy	1	261.1	100.0	100.0	6007.9	7455.3	7059.8
<input checked="" type="checkbox"/>	PTV_6600	Approved	72Gy	1	184.7	100.0	100.0	6732.3	7455.3	7158.5
<input checked="" type="checkbox"/>	PTV_7200	Approved	72Gy	1	88.7	100.0	100.0	548.2	7236.5	4599.9
<input checked="" type="checkbox"/>	Rectum	Approved	72Gy	1	14.2	100.0	100.1	6534.5	7294.2	6939.7
<input checked="" type="checkbox"/>	SeminalVesicle	Approved	72Gy	1	197.3	100.0	100.0	17.3	865.8	123.2
<input checked="" type="checkbox"/>	Sigma	Approved	72Gy	1						

File Edit View Measure Structure 4D Tools




Selection | Contouring | Image Registration | External Beam Planning | Brachytherapy Planning | Brachytherapy 2D Entry | Plan Evaluation

3D - CT\_VarLoc2 - 3/11/2019 9:16 AM



CT Image	RA1	RA1	CBCT 1	CT_VacLoc1	CT_VacLoc2	CT_hist	CBCT 1
CT_1 3/11/2019	CT 3/1/2019	CT 3/1/2019	CBCT 1 3/6/2019	CT 3/6/2019	CT 3/11/2019	CT_hist 3/14/2019	CBCT 1 3/12/2019



- Drawing Tool
- Select Structures
- Draw Planar Contour
  - Brush
  - Eraser
  - Draw Geometrical Shape
  - Create or Edit Annotation
  - Draw Volumetric Contour
  - Transform Structure
  - Deform Structure
- PET Subvolume Thresholding
- Image Thresholding
  - Search Body
  - Segmentation Wizard
  - Flood Fill
  - Margin for Structure
  - Post Processing
  - Extract Wall
  - Crop Structure
  - Boolean Operators
  - Extend Segmentation
  - Interpolate Structure
  - Segment High Density Artifacts
  - Clear Structure
- Move Marker or Isocenter Marker
- Edit Reference Points
- Draw Reference Line
- Calypso Beacon Detection



File Edit View Measure Structure 4D Tools




Selection Contouring Image Registration External Beam Planning Brachytherapy Planning Brachytherapy 2D Entry Plan Evaluation

Transversal - CT\_VacLoc2 - 3/11/2019 9:16 AM



CT\_VacLoc2  
 Bladder  
 BODY  
 Colon  
 CouchInterior  
 CouchSurface  
 CTV\_High  
 CTV\_Intermediate  
 FemoralJoint\_L  
 FemoralJoint\_R  
 Kidney\_L  
 Kidney\_R  
 PTV\_def  
 Rectum  
 seroma  
 SmallBowel  
 SpinalCord  
 sigma  
 User Origin



Standard, HFS

Z: -1.50 cm

(oncology)nina 3/12/2019 9:16 AM



Frontal - CT\_VacLoc2 - 3/11/2019 9:16 AM



Y: 2.29 cm

F

3D - CT\_VacLoc2 - 3/11/2019 9:16 AM



Sagittal - CT\_VacLoc2 - 3/11/2019 9:16 AM



X: -0.02 cm

F

Drawing Tool

Select Structures

- Draw Planar Contour
- Brush
- Eraser
- Draw Geometrical Shape
- Create or Edit Annotation
- Draw Volumetric Contour
- Transform Structure
- Deform Structure
- PET Subvolume Thresholding

Image Thresholding

Search Body

Segmentation Wizard

Flood Fill

Margin for Structure

Post Processing

Extract Wall

Crop Structure

Boolean Operators

Extend Segmentation

Interpolate Structure

Segment High Density Artifacts


Clear Structure

Move Marker or Isocenter Marker

Edit Reference Points

Draw Reference Line

Calypso Beacon Detection



File Edit View Measure Structure 4D Tools




Selection | Contouring | Image Registration | External Beam Planning | Brachytherapy Planning | Brachytherapy 2D Entry | Plan Evaluation

3D - CT\_VacLoc2 - 3/11/2019 9:16 AM



CT Image	CT 1	RA	RA1	CBCT 1	CT_VacLoc1	CT_VacLoc1	CT test	CBCT 1
	2/25/2019	3/1/2019	3/1/2019	3/6/2019	3/11/2019	3/14/2019	3/12/2019	



BODY (CT\_VacLoc2, CT\_VacLoc2)


- Drawing Tool
- Select Structures
- Draw Planar Contour
  - Brush
  - Eraser
  - Draw Geometrical Shape
  - Create or Edit Annotation
  - Draw Volumetric Contour
  - Transform Structure
  - Deform Structure
- PET Subvolume Thresholding
- Image Thresholding
  - Search Body
  - Segmentation Wizard
  - Flood Fill
  - Margin for Structure
  - Post Processing
  - Extract Wall
  - Crop Structure
  - Boolean Operators
  - Extend Segmentation
  - Interpolate Structure
  - Segment High Density Artifacts
  - Clear Structure
- Move Marker or Isocenter Marker
- Edit Reference Points
- Draw Reference Line
- Calypso Beacon Detection



TRIVA190225

C

PI1RA



Fields Dose Reference Points Dose Statistics

Show DVH	Structure	Approval Status	Plan	Course	Volume [cm³]	Dose Cover. [%]	Sampling Cover. [%]	Min Dose [cGy]	Max Dose [cGy]	Mean Dose [cGy]
✓	CTV_Intermediate	Approved	PI1RA	C	257.2	100.0	100.0	3499.8	4723.9	4562.7
✓	CTV_High	Approved	PI1RA	C	57.0	100.0	100.0	4363.2	4731.2	4539.7
✓	Colon	Approved	PI1RA	C	69.0	100.0	100.1	211.2	4309.5	1195.4
✓	Bladder	Approved	PI1RA	C	81.7	100.0	100.0	3276.2	4724.5	4334.9
✓	BODY	Approved	PI1RA	C	17716.9	100.0	100.0	9.6	4808.1	1294.2
✓	FemoralJoint_L	Approved	PI1RA	C	42.5	100.0	100.0	759.6	4437.9	1966.9
✓	FemoralJoint_R	Approved	PI1RA	C	43.1	100.0	100.0	782.3	4402.4	2012.0
✓	Kidney_R	Approved	PI1RA	C	114.4	100.0	99.8	18.0	582.2	99.5
✓	Rectum	Approved	PI1RA	C	36.1	100.0	100.0	592.7	4641.3	3706.6
✓	SmallBowel	Approved	PI1RA	C	335.8	100.0	100.1	0.0	4703.3	3616.6
✓	SpinalCord	Approved	PI1RA	C	34.3	100.0	100.1	102.2	4168.7	2252.3
✓	sygma	Approved	PI1RA	C	117.9	100.0	100.0	1901.5	4677.4	4082.4
✓	Kidney_L	Approved	PI1RA	C	84.7	100.0	99.8	16.6	216.8	74.0
✓	seroma	Approved	PI1RA	C	37.1	100.0	100.0	242.5	707.5	425.2
✓	PTV_def	Approved	PI1RA	C	880.1	100.0	100.0	1332.0	4808.1	4512.3




TRIVIA190225

C  
PI1RA


PI1RA - Treatment Approved - Transversal - CT\_VacLoc2

Color wash (%)  
106.8  
80.0  
60.0  
40.0  
20.0  
0.0



3D Dose MAX: 106.8 %  
3D MAX for PTV def: 106.8 %  
3D MIN for PTV def: 29.6 %  
3D MEAN for PTV def: 100.3 %



Dose Volume Histogram



PI1RA - Treatment Approved - Frontal - CT\_VacLoc2



PI1RA

- CT\_VacLoc2
- Registered Images
- CT\_VacLoc2
- Bladder
- BODY
- Colon
- CouchInterior
- CouchSurface
- CTV\_High
- CTV\_Intermediate
- FemoralJoint\_L
- FemoralJoint\_R
- Kidney\_L
- Kidney\_R
- PTV def
- Rectum
- seroma
- SmallBowel
- SpinalCord
- sigma
- User Origin
- Reference Points
- PTV def
- Dose
- Fields
- Isocenter Group I
- pi270
- pi270-DRR (Live)
- pi0
- pi0-DRR (Live)
- piCBCT
- piCBCT-DRR (Live)
- Field 2

Dose Reference Points Dose Statistics

Show DVH	Structure	Approval Status	Plan	Course	Volume [cm³]	Dose Cover. [%]	Sampling Cover. [%]	Min Dose [%]	Max Dose [%]	Mean Dose [%]
<input checked="" type="checkbox"/>	CTV_Intermediate	Approved	PI1RA	C	257.2	100.0	100.0	77.8	105.0	101.4
<input checked="" type="checkbox"/>	CTV_High	Approved	PI1RA	C	57.0	100.0	100.0	97.0	105.1	100.9
<input checked="" type="checkbox"/>	Colon	Approved	PI1RA	C	69.0	100.0	100.1	4.7	95.8	26.6
<input checked="" type="checkbox"/>	Bladder	Approved	PI1RA	C	81.7	100.0	100.0	72.8	105.0	96.3
<input checked="" type="checkbox"/>	BODY	Approved	PI1RA	C	17716.9	100.0	100.0	0.2	106.8	28.8
<input checked="" type="checkbox"/>	FemoralJoint_L	Approved	PI1RA	C	42.5	100.0	100.0	16.9	98.6	43.7
<input checked="" type="checkbox"/>	FemoralJoint_R	Approved	PI1RA	C	43.1	100.0	100.0	17.4	97.8	44.7
<input checked="" type="checkbox"/>	Kidney_R	Approved	PI1RA	C	114.4	100.0	99.8	0.4	12.9	2.2
<input checked="" type="checkbox"/>	Rectum	Approved	PI1RA	C	36.1	100.0	100.0	13.2	103.1	82.4
<input checked="" type="checkbox"/>	SmallBowel	Approved	PI1RA	C	335.8	100.0	100.1	0.0	104.5	80.4
<input checked="" type="checkbox"/>	SpinalCord	Approved	PI1RA	C	34.3	100.0	100.1	2.3	92.6	50.1
<input checked="" type="checkbox"/>	sigma	Approved	PI1RA	C	117.9	100.0	100.0	42.3	103.9	90.7
<input checked="" type="checkbox"/>	Kidney_L	Approved	PI1RA	C	84.7	100.0	99.8	0.4	4.8	1.6
<input checked="" type="checkbox"/>	seroma	Approved	PI1RA	C	37.1	100.0	100.0	5.4	15.7	9.4
<input checked="" type="checkbox"/>	PTV def	Approved	PI1RA	C	880.1	100.0	100.0	29.6	106.8	100.3

Ready

User: dr Neda Milosavljevic

Group: Oncologist

Site: Main

CAP NUM SCR

1:08 PM


5/8/2020



TRIVA190225

C


PI1RA



Fields Dose Reference Points Dose Statistics


Show DVH	Structure	Approval Status	Plan	Course	Volume [cm³]	Dose Cover. [%]	Sampling Cover. [%]	Min Dose [%]	Max Dose [%]	Mean Dose [%]
✓	CTV_Intermediate	Approved	PI1RA	C	257.2	100.0	100.0	77.8	105.0	101.4
✓	CTV_High	Approved	PI1RA	C	57.0	100.0	100.0	97.0	105.1	100.9
✓	Colon	Approved	PI1RA	C	69.0	100.0	100.1	4.7	95.8	26.6
✓	Bladder	Approved	PI1RA	C	81.7	100.0	100.0	72.8	105.0	96.3
✓	BODY	Approved	PI1RA	C	17716.9	100.0	100.0	0.2	106.8	28.8
✓	FemoralJoint_L	Approved	PI1RA	C	42.5	100.0	100.0	16.9	98.6	43.7
✓	FemoralJoint_R	Approved	PI1RA	C	43.1	100.0	100.0	17.4	97.8	44.7
✓	Kidney_R	Approved	PI1RA	C	114.4	100.0	99.8	0.4	12.9	2.2
✓	Rectum	Approved	PI1RA	C	36.1	100.0	100.0	13.2	103.1	82.4
✓	SmallBowel	Approved	PI1RA	C	335.8	100.0	100.1	0.0	104.5	80.4
✓	SpinalCord	Approved	PI1RA	C	34.3	100.0	100.1	2.3	92.6	50.1
✓	sygma	Approved	PI1RA	C	117.9	100.0	100.0	42.3	103.9	90.7
✓	Kidney_L	Approved	PI1RA	C	84.7	100.0	99.8	0.4	4.8	1.6
✓	seroma	Approved	PI1RA	C	37.1	100.0	100.0	5.4	15.7	9.4
✓	PTV def	Approved	PI1RA	C	880.1	100.0	100.0	29.6	106.8	100.3







TRIVIA19025

C  
PI1RA




Dose Reference Points Dose Statistics

Show DVH	Structure	Approval Status	Plan	Course	Volume [cm³]	Dose Cover.[%]	Sampling Cover.[%]	Min Dose [cGy]	Max Dose [cGy]	Mean Dose [cGy]
✓	CTV_Intermediate	Approved	PI1RA	C	257.2	100.0	100.0	3499.8	4723.9	4562.7
✓	CTV_High	Approved	PI1RA	C	57.0	100.0	100.0	4363.2	4731.2	4539.7
✓	Colon	Approved	PI1RA	C	69.0	100.0	100.1	211.2	4309.5	1195.4
✓	Bladder	Approved	PI1RA	C	81.7	100.0	100.0	3276.2	4724.5	4334.9
✓	BODY	Approved	PI1RA	C	17716.9	100.0	100.0	9.6	4808.1	1294.2
✓	FemoralJoint_L	Approved	PI1RA	C	42.5	100.0	100.0	759.6	4437.9	1966.9
✓	FemoralJoint_R	Approved	PI1RA	C	43.1	100.0	100.0	782.3	4402.4	2012.0
✓	Kidney_R	Approved	PI1RA	C	114.4	100.0	99.8	18.0	582.2	99.5
✓	Rectum	Approved	PI1RA	C	36.1	100.0	100.0	592.7	4641.3	3706.6
✓	SmallBowel	Approved	PI1RA	C	335.8	100.0	100.1	0.0	4703.3	3616.6
✓	SpinalCord	Approved	PI1RA	C	34.3	100.0	100.1	102.2	4168.7	2252.3
✓	sygma	Approved	PI1RA	C	117.9	100.0	100.0	1901.5	4677.4	4082.4
✓	Kidney_L	Approved	PI1RA	C	84.7	100.0	99.8	16.6	216.8	74.0
✓	seroma	Approved	PI1RA	C	37.1	100.0	100.0	242.5	707.5	425.2
✓	PTV def	Approved	PI1RA	C	880.1	100.0	100.0	1332.0	4808.1	4512.3

# IMAGE GUIDED RADIOTHERAPY - IGRT




- Kontrola korektne lokalizacije pacijenta, ciljnih volumena, organa od rizika prilikom svake frakcije zračenja
- Uz pomoć UZ, KV-imaging ili cone-beam CT

- Dodatna preciznost svih navedenih tehnika se postiže primenom jedne od sledećih tehnika tretmana:
- **zadržavanje daha**
- **adaptivno disanje (respiratory gating)**
- **slobodno disanje**
- **Respiratory gating** je tehnika kojom se koristi fiducijalni marker na zidu grudnog koša koji uključuje CT ili linearni akcelerator u određenoj fazi respiracije. Ova tehnika podrazumeva da je eksterni marker respiracije u korelaciji sa unutrašnjim kretanjem tumora, što nije uvek slučaj, i može varirati iz dana u dan.
- Prve dve metode se koriste kod bolesnika kod kojih postoji velika ekskurzija tumora pri respiraciji.



# STEREOTAKTIČNA RADIOTERAPIJA


- Visoko fokusiran tretman na male, dobro definisane mete bilo u jednoj frakciji (20Gy), ili u 1-4 frakcije (6Gy, 7Gy, 8Gy)
- Najčešće kod solitarnih meta promena, reiradijacija



zvor: Mayo Clinic. SRS.  
Radiosurgery.gr


# *Stereotactic Body Radiotherapy, SBRT*

- Upotreba ablativnih doza koje se isporučuju u malom broju frakcija, I čija je biološki ekvivalentna doza (BED)  $>100$  Gy.
- Prevenira tumorsku repopulaciju, izaziva vaskularno oštećenje, apoptozu endotela, remodelovanje mikrovaskulature, indukuje imunski odgovor na tumor.






# PROTONSKA TERAPIJA

- Karakteristična distribucije doze u ciljnog volumenu omogućava postizanje tumorske doze na određenoj dubini u tkivu uz poštenu normalnih struktura ispred i iza.
- Indikacije za zračenje tumora određenih lokalizacija – baza lobanje, CSI, retretman
- Nedostatak - cena mašine



## PROTON THERAPY



Izvor: [cancernetwork.com](http://cancernetwork.com)

# INTRAOPERATIVE RADIOTHERAPY (IORT)

- Intraoperativna radioterapija (IORT) podrazumeva isporuku radioterapijske doze u jednoj frakciji direktno na ležište tumora tokom operativnog zahvata pre nego što tumorske ćelije imaju mogućnost da proliferišu u postoperativnom toku.
- tkivo je vaskularizovano, što povećava efikasnost RT.
- Radioterapija se sprovodi direktnom vizualizacijom ležišta tumora tokom hirurške intervencije.
- IORT smanjuje neželjene radijacione komplikacije na koži, srcu i plućima, eliminiše mogućnost da pacijent iz različitih razloga ne kompletira preporučeni zračni tretman.
- Nedostatak IORT je što je definitivni Ph nalaz dostupan nakon sprovedene intervencije, te se ne mogu sa sigurnošću definisati resekcione marge – nedostatak na kome se poslednjih godina intenzivno radi, usavršavanjem tehnologije.
- Postoji više različitih tehnika iORT u zavisnosti od toga šta se koristi kao izvor zračenja, pa tako izvor mogu biti X zraci (Intrabeam)

- Ovaj sistem produkuje fotone niske energije (30- 50 KVp) sa brzim padom doze u tkivu i kao takav ne zahteva posebu zaštitu u prostoriji (operacionoj sali) u kojoj se procedura izvodi.
- Ceo tretman traje između 20 i 45 minuta u zavisnosti od veličine operativne šupljine dijametra aplikatora i propisane doze.
- TARGIT (2000 pacijenata iz 28 centara) je pokazala da nema statistički značajne razlike u stopi lokalnog relapsa i radijacionoj toksičnosti i predstavlja nivo dokaza I za primenu IORT.

- Precizna lokalizacija ležišta tumora i ciljana isporuka visoke radioterapijske doze (20-25 Gy u 1 frakciji)
- Minimalno izlaganje okolnih zdravstvenih struktura
- Mogućnost eskalacije doze (značajno veće od one koja može biti postignuta primenom transkutane zračne terapije)
- Mogućnost reiradijacije, posebno kod rekurentnih karcinoma
- IORT se može koristiti samostalno ili u kombinaciji sa transkutanom RT.
- Osim kod ranih karcinoma dojke IORT se može sprovoditi u većini intraabdominalnih tumora, rekurentnih kolorektalnih karcinoma, ginekoloških karcinoma, tumora mekih tkiva, te malignih tumora glave i vrata i pedijatrijskih tumora.

# BRAHITERAPIJA

- Preciznim pozicioniranjem radioaktivnog izvora u neposrednoj blizini tumora (do 2 cm) moguće je aplikovanje visoke doze zračenja na ciljni volumen.
- Zbog strmog perifernog pada doze, zdravo tkivo u neposrednoj blizini, je manje ozračeno od tumora, pa je i njegovo oporavljanje lakše
- Volumna doza je manja od one u transkutanoj radioterapiji, pa su rizici za lokalno i sistemsko oštećenje organizma znatno manji.

# Podela brahiterapije prema mestu aplikovanja izvora zračenja

- Površinska (kontaktna) brahiterapija izvodi se dovođenjem izvora u neposrednu blizinu, za zračenje tumora lokalizovanih na koži i vidljivim sluzokožama.
- Intrakavitarna (intraluminarna/endoluminalna) uvođenjem radioizotopa u prirodne tjelesne šupljine pomoću vodiča/aplikatora.
- Intersticijalna brahiterapija gdje se izvori zračenja uvode direktno u tumor, kroz šuplje vodiče u obliku igala, koje se zabadaju u tumorsko tkivo ili ubacivanjem radioaktivnih zrnaca u tumor.

